[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=9036a38ab55c70e01b4e0a275f8a69480f8d3de09ef9c8b64e0dbdc34ddc7234",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753221603,
      "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 136038357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=9036a38ab55c70e01b4e0a275f8a69480f8d3de09ef9c8b64e0dbdc34ddc7234"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=e3262fed71dadb6069484f178dc0534e40c34e7b004b2207c3f3721c549104d3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753202220,
      "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 136043445,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=e3262fed71dadb6069484f178dc0534e40c34e7b004b2207c3f3721c549104d3"
    }
  },
  {
    "ts": null,
    "headline": "Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement",
    "summary": "Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming milestones.",
    "url": "https://finnhub.io/api/news?id=da32dd96dfa28ed33587dc4c3eb3773289637020ef818dadd03198b9854c5153",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753174927,
      "headline": "Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement",
      "id": 136030925,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212517857/image_2212517857.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming milestones.",
      "url": "https://finnhub.io/api/news?id=da32dd96dfa28ed33587dc4c3eb3773289637020ef818dadd03198b9854c5153"
    }
  }
]